Philip N Hawkins

List of Publications by Citations

101 papers	10,300 citations	40 h-index	101 g-index
111 ext. papers	12,408 ext. citations	7.4 avg, IF	5.85 L-index

#	Paper	IF	Citations
101	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. *Nature*, **1997**, 385, 787-93	50.4	980
100	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *American Journal of Hematology*, **2005**, 79, 319-28	7.1	971
99	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12	16.7	792
98	Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. *Arthritis and Rheumatism*, **2004**, 50, 607-12		650
97	New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9	2.2	553
96	Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. *New England Journal of Medicine*, **2002**, 346, 1786-91	59.2	516
95	Systemic amyloidosis. *Lancet, The*, **2016**, 387, 2641-2654	40	475
94	Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. *New England Journal of Medicine*, **1990**, 323, 508-13	59.2	422
93	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. *Circulation*, **2015**, 132, 1570-9	16.7	320
92	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). *Clinical Genetics*, **1991**, 40, 242-6	4	278
91	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, **2013**, 121, 3420-7	2.2	267
90	Native T1 mapping in transthyretin amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 157-65	8.4	265
89	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. *New England Journal of Medicine*, **2015**, 373, 1106-14	59.2	250
88	T1 mapping and survival in systemic light-chain amyloidosis. *European Heart Journal*, **2015**, 36, 244-51	9.5	247
87	EULAR recommendations for the management of familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2016**, 75, 644-51	2.4	241
86	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, **2015**, 126, 612-5	2.2	232
85	Systemic immunoglobulin light chain amyloidosis. *Nature Reviews Disease Primers*, **2018**, 4, 38	51.1	207

84	CMR-based differentiation of AL and ATTR cardiac amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 133-42	8.4	182
83	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. *Journal of the American College of Cardiology*, **2017**, 70, 466-477	15.1	176
82	Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. *Human Mutation*, **2014**, 35, E2403-12	4.7	162
81	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. *British Journal of Haematology*, **2000**, 110, 454-60	4.5	155
80	Amyloidosis: a review of recent diagnostic and therapeutic developments. *British Journal of Haematology*, **1997**, 99, 245-56	4.5	143
79	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1289-98	4.1	131
78	Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. *Current Opinion in Nephrology and Hypertension*, **2002**, 11, 649-55	3.5	108
77	Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. *American Journal of Medicine*, **2006**, 119, 355.e15-24	2.4	101
76	Native T1 and Extracellular Volume in Transthyretin Amyloidosis. *JACC: Cardiovascular Imaging*, **2019**, 12, 810-819	8.4	89
75	SAA1 alleles as risk factors in reactive systemic AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **1998**, 5, 262-5	2.7	84
74	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). *Haematologica*, **2014**, 99, 1479-85	6.6	83
73	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. *Blood*, **2019**, 134, 2271-2280	2.2	77
72	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. *Lancet Haematology,the*, **2015**, 2, e241-50	14.6	76
71	Systemic amyloidosis. *Current Opinion in Pharmacology*, **2006**, 6, 214-20	5.1	73
70	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. *British Journal of Haematology*, **2006**, 134, 417-25	4.5	72
69	Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. *Clinical Science*, **1994**, 87, 289-95	6.5	70
68	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology. *JACC: Cardiovascular Imaging*, **2019**, 12, 1958-1969	8.4	66
67	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 709-13	8.8	57

66	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. *JACC: Cardiovascular Imaging*, **2019**, 12, 823-833	8.4	55
65	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. *Rheumatology*, **2017**, 56, 2102-2108	3.9	54
64	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *European Heart Journal*, **2020**, 41, 1439-1447	9.5	50
63	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. *Journal of Clinical Oncology*, **2016**, 34, 2037-45	2.2	46
62	Allogeneic bone marrow transplantation for systemic AL amyloidosis. *British Journal of Haematology*, **1998**, 100, 226-8	4.5	45
61	Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. *Radiology*, **2013**, 268, 858-64	20.5	40
60	Diagnostic imaging of cardiac amyloidosis. *Nature Reviews Cardiology*, **2020**, 17, 413-426	14.8	39
59	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration. *Rheumatology*, **2017**, 56, 209-213	3.9	38
58	An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q. *Arthritis and Rheumatism*, **2000**, 43, 2034-40		37
57	Hereditary systemic amyloidosis with renal involvement. *Journal of Nephrology*, **2003**, 16, 443-8	4.8	29
56	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. *Journal of Cardiology Cases*, **2011**, 4, e93-e97	0.6	24
55	Emerging treatments for amyloidosis. *Kidney International*, **2015**, 87, 516-26	9.9	20
54	Two types of amyloid in a single heart. *Blood*, **2014**, 124, 3025-7	2.2	20
53	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. *Scientific Reports*, **2019**, 9, 1388	4.9	15
52	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. *Blood*, **2010**, 116, 1364-1364	2.2	15
51	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. *Journal of the American Heart Association*, **2019**, 8, e012097	6	14
50	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia*, **2020**, 34, 1187-1191	10.7	12
49	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. *Haematologica*, **2014**, 99, e260-3	6.6	11

48	001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. *Heart*, **2017**, 103, A1-A2	5.1	11
47	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis Results From the UK Amyloidosis Treatment Trial.. *Blood*, **2009**, 114, 2869-2869	2.2	10
46	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. *European Heart Journal*, **2021**,	9.5	9
45	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. *Blood*, **2006**, 108, 129-129	2.2	8
44	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. *Haematologica*, **2017**, 102, e411-e414	6.6	7
43	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1995**, 2, 163-166	2.7	7
42	TRAP1 chaperone protein mutations and autoinflammation. *Life Science Alliance*, **2020**, 3,	5.8	7
41	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. *JACC: Cardiovascular Imaging*, **2020**, 13, 2546-2557	8.4	7
40	Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. *Circulation: Cardiovascular Imaging*, **2021**, CIRCIMAGING121012506	3.9	7
39	Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. *American Journal of Clinical Pathology*, **2016**, 146, 78-85	1.9	7
38	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. *Blood*, **2009**, 114, 2796-2796	2.2	6
37	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. *Blood*, **2009**, 114, 745-745	2.2	6
36	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 1304-1311	4.1	6
35	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. *Blood*, **2004**, 104, 755-755	2.2	5
34	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. *Blood*, **2008**, 112, 869-869	2.2	4
33	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. *Blood*, **2010**, 116, 988-988	2.2	4
32	ALchemy - A Large Prospective Real World' Study of Chemotherapy in AL Amyloidosis. *Blood*, **2011**, 118, 992-992	2.2	4
31	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. *Sleep Medicine*, **2017**, 32, 191-197	4.6	3

30	Six-minute walk test (6MWT) in AL amyloidosis - baseline and 12-month follow-up after chemotherapy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 62-63	2.7	3
29	Two types of systemic amyloidosis in a single patient. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2020**, 27, 275-276	2.7	3
28	Recognising and understanding cryopyrin-associated periodic syndrome in adults. *British Journal of Nursing*, **2019**, 28, 1180-1186	0.7	3
27	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. *Blood*, **2008**, 112, 1689-1689	2.2	3
26	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. *Blood*, **2009**, 114, 1791-1791	2.2	3
25	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. *Blood*, **2011**, 118, 995-995	2.2	3
24	Acute hepatitis in a child heterozygous for the I259V MEFV gene variant. *Prague Medical Report*, **2014**, 115, 128-33	0.7	3
23	Search for AL amyloidosis risk factors using Mendelian randomization. *Blood Advances*, **2021**, 5, 2725-2734	7.8	3
22	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 273-281	4.1	3
21	Role of Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis. *British Journal of Haematology*, **2018**, 183, 506-509	4.5	3
20	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. *Blood*, **2005**, 106, 3495-3495	2.2	2
19	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 72-73	2.7	1
18	Hyperimmunoglobulin D syndrome in an Indian family undiagnosed for 11 years. *International Journal of Rheumatic Diseases*, **2017**, 20, 2236-2237	2.3	1
17	The UK National Amyloidosis Centre. *European Heart Journal*, **2019**, 40, 1661-1664	9.5	1
16	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. *Blood*, **2020**, 136, 40-40	2.2	1
15	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. *Blood*, **2008**, 112, 1733-1733	2.2	1
14	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2966-2966	2.2	1
13	The Prognostic Significance of Phenotypically Normal Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. *Blood*, **2014**, 124, 2073-2073	2.2	1

12	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. *Blood*, **2011**, 118, 3975-3975	2.2	1
11	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. *Blood*, **2012**, 120, 4074-4074	2.2	1
10	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. *Blood*, **2011**, 118, 3978-3978	2.2	0
9	Superior mesenteric artery syndrome in a young girl following spinal surgery for scoliosis. *British Journal of Hospital Medicine (London, England: 2005)*, **2005**, 66, 700-1	0.8	
8	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. *Blood*, **2004**, 104, 4875-4875	2.2	
7	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. *Blood*, **2014**, 124, 305-305	2.2	
6	Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). *Blood*, **2014**, 124, 1198-1198	2.2	
5	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. *Blood*, **2009**, 114, 2814-2814	2.2	
4	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. *Blood*, **2009**, 114, 1863-1863	2.2	
3	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. *Blood*, **2010**, 116, 3958-3958	2.2	
2	Systemic Amyloidosis886-892		
1	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2978-2978	2.2	